Summary
The response contains multiple claims not supported or contradicted by the provided FDA label excerpts (which include only pregnancy-related labeling). Because the majority of claims concern cost/availability/insurance and general drug class/side effects not present in the supplied label text, label alignment cannot be established and the overall evaluation is therefore not reliable.
Category Scores
Accurate Statements
Telmisartan is an angiotensin II receptor blocker (ARB).
No support evaluable from the provided label excerpts (only pregnancy-related sections 5.1/8.1/17 are supplied; ARB identity is not stated there).
Unsupported Statements
Telmisartan 80 mg tablets are generally less expensive in generic versions than in branded ones.
Not supported by the provided MICARDIS label excerpts.
Generic Telmisartan 80 mg tablets are widely available.
Not supported by the provided MICARDIS label excerpts.
Generic Telmisartan 80 mg tablets typically cost approximately $10 to $30 for a 30-day supply.
Not supported by the provided MICARDIS label excerpts.
Most insurance plans provide coverage for Telmisartan, particularly for generic versions.
Not supported by the provided MICARDIS label excerpts.
The exact co-payment amount for Telmisartan depends on the specific insurance policy and whether the pharmacy is in-network.
Not supported by the provided MICARDIS label excerpts.
Telmisartan is an angiotensin II receptor blocker (ARB).
The supplied label excerpts do not state this; therefore cannot be confirmed against the provided text.
ARBs lower blood pressure by blocking the action of angiotensin II, a substance that narrows blood vessels.
Not supported by the provided MICARDIS label excerpts.
Other classes of blood pressure medications, such as ACE inhibitors, calcium channel blockers, and diuretics, work through different mechanisms to achieve a similar effect.
Not supported by the provided MICARDIS label excerpts.
Once Telmisartan patents expire, generic versions become available.
Not supported by the provided MICARDIS label excerpts.
After patent expiration, increased competition leads to lower prices for Telmisartan.
Not supported by the provided MICARDIS label excerpts.
Common side effects of Telmisartan include dizziness.
The provided MICARDIS label excerpts do not list dizziness as a side effect.
Common side effects of Telmisartan include fatigue.
The provided MICARDIS label excerpts do not list fatigue as a side effect.
Common side effects of Telmisartan include low blood pressure.
The provided excerpts discuss fetal/neonatal hypotension risk in pregnancy; they do not provide general adult/common adverse reaction frequency.
Less common but more serious side effects of Telmisartan may include kidney problems.
The provided excerpts discuss fetal/neonatal renal failure/anuria risk; they do not provide general adult adverse reaction frequency or categorization.
Telmisartan-associated kidney problems may be more likely in individuals with pre-existing kidney disease or heart failure.
Not supported by the provided MICARDIS label excerpts.
Contradictions
Important Omissions
No label-supported dosing/administration, indication, contraindications, boxed warnings, drug interactions, or monitoring statements from the MICARDIS label were provided, despite many claims being safety-related and population-related.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The supplied claims do not directly contradict pregnancy risk language in the provided excerpts; however, most safety-related assertions (side effect frequency/severity and risk factors) are unsupported by the provided label text, limiting label-based safety validation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Most claims are not supported by the provided MICARDIS label excerpts and include cost/coverage statements and general adverse-effect assertions not contained in the supplied FDA-approved text.
Suggested Improvement
Limit statements to what is actually present in the supplied label sections (5.1/8.1/17) or provide additional label sections (e.g., Indications, Dosage, Contraindications, Warnings/Precautions, Adverse Reactions) for evaluation; remove or qualify unsupported claims about pricing, availability, insurance, and general side-effect frequency.